FDA approves Admelog, the first short-acting “follow-on” insulin product to treat diabetes
11/12/2017
Leggi
Breaking news
Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
Zinman B, Marso SP, Poulter NR et al.
Diabetologia 2018 61(1):48-57
Leggi
Spectrum of mutations in monogenic diabetes genes identified from high-throughput DNA sequencing of 6888 individuals
Bansal V, Gassenhuber J, Phillips T, et al.
BMC Medicine. Pub. online 6 December 2017
Leggi
How Pure is PURE? Dietary Lessons Learned and Not Learned From the PURE Trials
Gianos E, Williams KA, Freeman AM, et al.
Am J Med. Pub. online 8 December 2017
Leggi
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
Bethel MA
Lancet Diabetes Endocrinol. Pub. online 5 December 2017
Leggi
DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality
Pieber TR, Marso SP, McGuire DK, et al.
Diabetologia 2018;61(1):58-65
Leggi
Maternal obesity as a risk factor for early childhood type 1 diabetes: a nationwide, prospective, population-based case–control study
Lindell N, Carlsson A, Josefsson A, et al.
Diabetologia 2018; 61(1):130-7
Leggi
The Potential Impact of Food Taxes and Subsidies on Cardiovascular Disease and Diabetes Burden and Disparities in the United States
Peñalvo JL, Cudhea F, Micha R
BMC Medicine. Published on: 27 November 2017
Leggi
Repaglinide Versus Insulin For Newly Diagnosed Diabetes In Patients With Cystic Fibrosis: A Multicentre, Open-Label, Randomised Trial
Ballmann M, Hubert D, Assael BM, et al.
The Lancet Diabetes & Endocrinology. Pub. online 30 November 2017.
Leggi
Cystic-Fibrosis-Related Diabetes: Time for Oral Drugs?
Moran A
The Lancet Diabetes & Endocrinology. Pub. online 30 November 2017.
Leggi